A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

NCT04416035 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

608

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer

Interventions

BIOLOGICAL: TRS003
BIOLOGICAL: China-approved Bevacizumab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Zhejiang Teruisi Pharmaceutical Inc.